Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis
Qiying Chen, Tianyu Chen, Weicheng Lin, Xi Chen · 2026
Read Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis by Qiying Chen, Tianyu Chen, Weicheng Lin, Xi Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0351059.txt.
Description
Qiying Chen and colleagues compared two weekly and daily style diabetes drugs for cost and health value in China. Both drugs help control blood sugar in type two diabetes. A model followed a virtual cohort for twenty five years, using British long term risk equations and head to head trial data, with Chinese costs and quality of life weights.
Semaglutide cost more overall and gained a bit more quality adjusted life than dulaglutide. Extra cost per added quality year landed near twice yearly income per person, inside the range Chinese guidance counts as acceptable. Checks on uncertain inputs left the verdict steady. Payers can defend the pricier drug on value grounds, though budgets will still feel the higher spend.
Catalog record
| CREATOR | Qiying Chen, Tianyu Chen, Weicheng Lin, Xi Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43374 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |